content/01.introduction.md:8:adenocarcinomas
content/01.introduction.md:8:alveoli
content/01.introduction.md:8:BRAF
content/01.introduction.md:8:EGFR
content/01.introduction.md:8:genomic
content/01.introduction.md:8:genomic
content/01.introduction.md:8:histological
content/01.introduction.md:8:histological
content/01.introduction.md:8:KRAS
content/01.introduction.md:8:MAPK
content/01.introduction.md:8:NSCLC
content/01.introduction.md:8:NSCLC
content/01.introduction.md:8:NSCLC
content/01.introduction.md:8:SCLC
content/01.introduction.md:8:subtype
content/01.introduction.md:8:subtype
content/01.introduction.md:12:ALK
content/01.introduction.md:12:BRAF
content/01.introduction.md:12:Carboplatin
content/01.introduction.md:12:Cisplatin
content/01.introduction.md:12:EGFR
content/01.introduction.md:12:LUAD
content/01.introduction.md:12:Paclitaxel
content/01.introduction.md:12:Pemetrexed
content/01.introduction.md:12:ROS
content/01.introduction.md:12:TRK
content/01.introduction.md:14:Altekruse
content/01.introduction.md:14:Arai
content/01.introduction.md:14:Duggan
content/01.introduction.md:14:histological
content/01.introduction.md:14:Jemal
content/01.introduction.md:14:microenvironment
content/01.introduction.md:14:Minna
content/01.introduction.md:14:oncogenic
content/01.introduction.md:14:paraneoplastic
content/01.introduction.md:14:Penberthy
content/01.introduction.md:14:radiograph
content/01.introduction.md:14:Siegel
content/01.introduction.md:14:subtypes
content/01.introduction.md:16:BRAF
content/01.introduction.md:16:LUAD
content/01.introduction.md:18:adenomas
content/01.introduction.md:18:BRAF
content/01.introduction.md:18:BRAF
content/01.introduction.md:18:BRAF
content/01.introduction.md:18:BRAF
content/01.introduction.md:18:GEMMs
content/01.introduction.md:18:Hanahan
content/01.introduction.md:18:Hanahan
content/01.introduction.md:18:KRAS
content/01.introduction.md:18:MAPK
content/01.introduction.md:18:oncogenic
content/01.introduction.md:18:pneumocytes
content/01.introduction.md:18:Surfactant
content/01.introduction.md:18:WNT
content/01.introduction.md:20:proto
content/01.introduction.md:22:MAPK
content/01.introduction.md:24:ARAF
content/01.introduction.md:24:BRAF
content/01.introduction.md:24:BRAF
content/01.introduction.md:24:constitutively
content/01.introduction.md:24:CRAF
content/01.introduction.md:24:EGF
content/01.introduction.md:24:ERK
content/01.introduction.md:24:GTP
content/01.introduction.md:24:GTP
content/01.introduction.md:24:kinases
content/01.introduction.md:24:kinases
content/01.introduction.md:24:kinases
content/01.introduction.md:24:kinases
content/01.introduction.md:24:Kinases
content/01.introduction.md:24:ligand
content/01.introduction.md:24:ligand
content/01.introduction.md:24:ligands
content/01.introduction.md:24:MAPK
content/01.introduction.md:24:MAPK
content/01.introduction.md:24:MEK
content/01.introduction.md:24:mitogens
content/01.introduction.md:24:oncogenic
content/01.introduction.md:24:oncogenic
content/01.introduction.md:24:phosphorylates
content/01.introduction.md:24:phosphorylates
content/01.introduction.md:24:RAS
content/01.introduction.md:24:RAS
content/01.introduction.md:24:RAS
content/01.introduction.md:24:RTKs
content/01.introduction.md:24:RTKs
content/01.introduction.md:24:transcriptional
content/01.introduction.md:24:Tyrosine
content/01.introduction.md:26:BRAF
content/01.introduction.md:26:BRAF
content/01.introduction.md:26:BRAF
content/01.introduction.md:26:Dabrafenib
content/01.introduction.md:26:kinases
content/01.introduction.md:26:MAPK
content/01.introduction.md:26:MEK
content/01.introduction.md:26:MEK
content/01.introduction.md:26:pre
content/01.introduction.md:26:Trametinib
content/01.introduction.md:28:GEMMs
content/01.introduction.md:30:DMBA
content/01.introduction.md:30:FVB
content/01.introduction.md:30:GEMMs
content/01.introduction.md:30:lethality
content/01.introduction.md:30:lethality
content/01.introduction.md:32:Cre
content/01.introduction.md:32:Cre
content/01.introduction.md:32:inducible
content/01.introduction.md:32:KRAS
content/01.introduction.md:32:LoxP
content/01.introduction.md:32:LoxP
content/01.introduction.md:32:LoxP
content/01.introduction.md:32:polyadenylation
content/01.introduction.md:32:recombinase
content/01.introduction.md:34:BRAF
content/01.introduction.md:34:preclinical
content/01.introduction.md:34:transcriptional
content/01.introduction.md:36:BRAF
content/01.introduction.md:38:BRAF
content/01.introduction.md:38:BRAF
content/01.introduction.md:38:BRAF
content/01.introduction.md:38:BRAF
content/01.introduction.md:38:CAAX
content/01.introduction.md:38:cDNA
content/01.introduction.md:38:Cre
content/01.introduction.md:38:Cre
content/01.introduction.md:38:fluorophore
content/01.introduction.md:38:LoxP
content/01.introduction.md:38:LoxP
content/01.introduction.md:38:onco
content/01.introduction.md:38:oncoprotein
content/01.introduction.md:38:TdTomato
content/01.introduction.md:40:egfr
content/01.introduction.md:40:erk
content/01.introduction.md:40:mek
content/01.introduction.md:40:ras
content/01.introduction.md:42:luad
content/01.introduction.md:42:tumorigenesis
content/01.introduction.md:44:BRAF
content/01.introduction.md:44:gemms
content/01.introduction.md:48:wnt
content/01.introduction.md:50:ERK
content/01.introduction.md:50:MEK
content/01.introduction.md:50:RAS
content/01.introduction.md:56:WNT
content/01.introduction.md:58:decameric
content/01.introduction.md:58:oligomerization
content/01.introduction.md:58:tetramerization
content/01.introduction.md:58:transactivation
content/01.introduction.md:58:transactivation
content/01.introduction.md:58:transcriptional
content/01.introduction.md:58:transcriptional
content/01.introduction.md:58:transcriptional
content/01.introduction.md:60:Fraumeni
content/01.introduction.md:60:leukemias
content/01.introduction.md:64:phenotypes
content/01.introduction.md:64:stressor
content/01.introduction.md:66:cDNA
content/01.introduction.md:66:ectopic
content/01.introduction.md:66:misclassification
content/01.introduction.md:66:RAS
content/01.introduction.md:68:hemizygosity
content/01.introduction.md:68:hotspot
content/01.introduction.md:68:hotspots
content/01.introduction.md:68:tetramer
content/01.introduction.md:68:transcriptional
content/01.introduction.md:70:arnie
content/01.introduction.md:70:Bougeard
content/01.introduction.md:70:chemoresistance
content/01.introduction.md:70:Fraumeni
content/01.introduction.md:70:Fraumeni
content/01.introduction.md:70:GOF
content/01.introduction.md:70:GOF
content/01.introduction.md:70:LOF
content/01.introduction.md:70:LOF
content/01.introduction.md:70:missense
content/01.introduction.md:70:missense
content/01.introduction.md:70:tumorigenic
content/01.introduction.md:72:Catenin
content/01.introduction.md:72:CREB
content/01.introduction.md:72:GOF
content/01.introduction.md:72:KRAS
content/01.introduction.md:72:Lozano
